- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03283956
Safety and Efficacy of dRug-ElutiNg beADs Trans-arterial chemoEmbolization for Hepatocellular Carcinoma in Taiwan (SERENADE-T)
Safety and Efficacy of dRug-ElutiNg beADs Trans-arterial chemoEmbolization for Hepatocellular Carcinoma in Taiwan (SERENADE-T)
Study Overview
Status
Intervention / Treatment
Detailed Description
To evaluate efficacy and safety profile of DC bead TACE in patients with hepatocellular carcinoma in Taiwan.
This is a multi-center, retrospective, single arm study to explore safety and efficacy of DC bead TACE in hepatocellular carcinoma (HCC) in Taiwan
Retrospective analysis of medical records of all patients who underwent DC Bead TACE at National Taiwan University Hospital, National Cheng Kung University Hospital, and Taichung Veterans General Hospital from 2010-2017/7.
All statistical data were analyzed with SPSS software (SPSS, IBM North America, New York, NY, USA). Demographic and baseline lab data are presented by using descriptive statistics Student's t-test. Survival analysis will includes all patients.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Chien-Hung Chen, MD
- Phone Number: 65923 886-2-23123456
- Email: chenhcc@ntuh.gov.tw
Study Locations
-
-
-
Taipei, Taiwan
- National Taiwan University Hospital
-
Contact:
- Chien-Hung Chen, MD
- Phone Number: 65923 886-2-23123456
- Email: chenhcc@ntuh.gov.tw
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with a diagnosis of HCC, according to the AASLD diagnosis criteria for HCC.
- Patient received DC bead TACE.
Exclusion Criteria:
- Patients with current any other cancer except non-melanomatous skin cancer.
- Infiltrative HCC
- Patients received ≥2 consecutive sessions of TACE (≥2 TACE at the same admission, no matter it is cTACE or DC bead TACE)
- Patients received DC bead TACE and simultaneously received other therapy, such as radiotherapy, sorafenib etc.
- Presence of collateral vessel pathways potentially endangering normal territories during embolization.
- Presence of arteries supplying the lesion not large enough to accept DC Bead® microspheres.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Patient records
Medical records of all patients who underwent DC bead TACE.
|
Retrospective analysis of medical records of all patients who underwent DC Bead TACE at National Taiwan University Hospital, National Cheng Kung University Hospital, and Taichung Veterans General Hospital from 2010-2017/7
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety of the DC bead TACE
Time Frame: One year.
|
Safety of the DC bead TACE is evaluated based on the incidence of Grade 3 and Grade 4 toxicities up to 8 weeks following the procedure according to National Cancer Institute's Common Terminology Criteria for adverse events (CTCAE Version 4.03).
|
One year.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tumor response
Time Frame: One year.
|
Tumor response is assessed on triphase CT or contrast-enhanced MR study according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria.
|
One year.
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 201708028RINC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatocellular Carcinoma Non-resectable
-
Omega TherapeuticsRecruitingHepatocellular Carcinoma | Solid Tumor | Liver Cancer | Hepatocellular Carcinoma Non-resectable | Hepatocellular Cancer | Hepatocellular Carcinoma Recurrent | Liver, Cancer of, Non-ResectableUnited States, Hong Kong, Korea, Republic of, Singapore, Taiwan
-
Institut für Klinische Krebsforschung IKF GmbH...IpsenRecruitingHepatocellular Carcinoma Non-resectable | Metastatic Hepatocellular CarcinomaGermany
-
Tongji HospitalGeneplus-Beijing Co. Ltd.RecruitingHepatocellular Carcinoma Non-resectableChina
-
Assistance Publique - Hôpitaux de ParisLaboratoire EISAINot yet recruitingHepatocellular Carcinoma Non-resectableFrance
-
Wan-Guang ZhangThe Second Affiliated Hospital of Fujian Medical University; Geneplus-Beijing... and other collaboratorsRecruitingHepatocellular Carcinoma Non-resectableChina
-
Zhujiang HospitalNot yet recruitingHepatocellular Carcinoma Non-resectable
-
Jinan Military General HospitalRecruitingHepatocellular Carcinoma Non-resectableChina
-
Jiangsu HengRui Medicine Co., Ltd.CompletedHepatocellular Carcinoma Non-ResectableChina
-
Second Affiliated Hospital of Guangzhou Medical...CompletedHepatocellular Carcinoma Non-resectableChina
-
Second Affiliated Hospital of Guangzhou Medical...CompletedHepatocellular Carcinoma Non-resectableChina
Clinical Trials on Patient records
-
University at BuffaloCompleted
-
University of SussexUniversity of Cape Town; Africa Health Research InstituteNot yet recruiting
-
Severance HospitalCompletedKidney TransplantationKorea, Republic of
-
Association pour le Développement et l'Organisation...Completed
-
HaEmek Medical Center, IsraelUnknownThrombosis | PrematureIsrael
-
HaEmek Medical Center, IsraelCompletedHemolytic Anemia | Thalassemia AlphaIsrael
-
Association des Réseaux BronchioliteLaboratoire Système et Matériaux pour la Mécatronique (SYMME)Recruiting
-
HaEmek Medical Center, IsraelCompleted
-
University Hospital, MontpellierCompleted
-
National Taiwan University HospitalUnknownPelvic Organ ProlapseTaiwan